ArticleJHLT open2026
The role of high-sensitivity troponin in identifying patients with cardiac allograft rejection.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Serial Cardiac Troponin I Kinetics Do Not Improve Detection of Acute Cellular Rejection Beyond Concurrent Troponin Levels After Heart Transplantation.Journal of clinical medicine · 2026Article
- From rejection to vasculopathy: a review of non-invasive biomarkers in alloimmune responses in heart transplantation.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Biomarkers for acute rejection diagnosis are frequently searched, and data from medical literature are conflicting. The role of high-sensitivity troponin I in the diagnosis of acute cellular rejection (ACR) after heart transplant (HT) is uncertain. However, it is a widely used and accessible tool in developing countries. Objective: This study aims to determine whether hs-TnI can serve as a reliable and accessible tool to identify patients with clinically significant rejection (ACR >2R) in a real-world Latin American cohort that has different etiologies than the epidemiology of the main trials. Methods: In this retrospective cohort, we evaluated data from electronic records of HT recipients submitted to HT from March, 2020 to September, 2022 using REdCAp database. All patients who underwent endomyocardial biopsies (EMB) between 3 months and 2 years of HT and had samples of HS-troponin I previously measured were included in this study. The HS-troponin levels were compared between patients with ACR higher or lower than 2R. Results: In this analysis, we included data from 187 biopsies performed at least 3 months after HT in 94 recipients who had paired Hs-troponin I samples collected. Fifty-four (57%) were men, and their median age at heart transplant was 48 ±11 years. The median hs-TnI levels were 29 (11-118) ng/L. ACR > 2R was observed in 48 EMB and the median hs-TnI levels were 69 (26-224) ng/L, which was significantly higher than levels observed in patients with grade 0R/1R [21 (9-64) ng/L, Conclusion: In this cohort, HS-troponin I was able to identify patients with acute cellular rejection. This is the largest Latin American cohort assessing hs-TnI after HT, and the first to explore its performance across specific etiologies, including Chagas disease. Prospective studies may confirm the role of HS-troponin I as a biomarker of acute rejection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.